Sweden's TLV Grants Limited Reimbursement for Avapritinib (Ayvakyt) in GIST and Systemic Mastocytosis

Sweden's TLV granted limited reimbursement for avapritinib (Ayvakyt) in GIST and systemic mastocytosis on 24 March 2026, effective April 2026. The decision reinforces Nordic HTA willingness to accept single-arm trial evidence in high-need rare oncology and illustrates the indirect treatment comparison and health economic modelling demands for sponsors pursuing further European submissions.